BOSTON IVF

2024 saw pivotal healthcare advances, including a breakthrough HIV study with 100% prevention via twice-yearly injections, in-line hemolysis detection on blood gas analyzers, FDA approval of gene therapies Casgevy and Lyfgenia for sickle cell disease, and IVF research enabling multiple births from one cycle. Focused ultrasound for brain cancer treatment and AI advancements in surgical planning were also highlighted.

In 2023, private equity dealmaking in U.S. healthcare declined for the second consecutive year, influenced by macroeconomic challenges like high interest rates and labor shortages. Despite this, 1135 unique deals were identified, with outpatient care, dental care, health IT, and medtech being the busiest subsectors. Private equity's growing presence raises concerns over cost-cutting and debt service obligations potentially impacting patient care and worker compensation. Regulators and lawmakers are urged to scrutinize private equity acquisitions more closely to ensure affordable and quality healthcare.